Arca
Skip to content
Tools
Tools

LAG3: Lymphocyte activation gene 3 protein

[Lymphocyte activation gene 3 protein]: Inhibitory receptor on antigen activated T-cells.

  • Drugs that act on it: 6
  • Approved: 1
  • In phases 1 to 3: 5
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on LAG3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 5
  • Other 1

Approved1

  • Relatlimab

Phase 32

  • Fianlimab
  • Favezelimab

Phase 23

  • Eftilagimod alfa
  • Ieramilimab
  • Tebotelimab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 6 act as: Lymphocyte activation gene 3 protein inhibitor; the rest name their own mechanism.
    RelatlimabApprovedBristol-Myers SquibbAntibodyInhibitor55
    FianlimabPhase 3RegeneronAntibodyInhibitor35
    FavezelimabPhase 3Merck & Co. (MSD)AntibodyInhibitor3
    Eftilagimod alfaPhase 2IMMUTEPOtherVaccine antigenLymphocyte activation gene 3 protein vaccine antigen4
    IeramilimabPhase 2Novartis PharmaceuticalsAntibodyInhibitor0
    TebotelimabPhase 2Zai LabAntibodyInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 23 in all, from ClinicalTrials.gov.
    Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell CarcinomaRelatlimabPhase 2Not yet recruitingMedical College of WisconsinOct 27, 2026
    A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)FianlimabPhase 2Not yet recruitingRegeneron PharmaceuticalsSep 9, 2026
    A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal CarcinomaFianlimabPhase 1Not yet recruitingMemorial Sloan Kettering Cancer CenterJun 16, 2026
    Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGRelatlimabPhase 2Not yet recruitingNationwide Children's HospitalJun 12, 2026
    MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RelatlimabPhase 2RecruitingSwiss Cancer InstituteMay 7, 2026
    A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A EpendymomaFianlimabPhase 1 / Phase 2Not yet recruitingRegeneron PharmaceuticalsMay 5, 2026
    Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaFianlimabPhase 2Not yet recruitingUniversity of California, IrvineApr 14, 2026
    PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaFianlimabPhase 2Not yet recruitingM.D. Anderson Cancer CenterApr 6, 2026
    ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRelatlimabPhase 2RecruitingNYU Langone HealthApr 1, 2026
    A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaRelatlimabPhase 4Not yet recruitingBristol-Myers SquibbMar 9, 2026
    A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and NeckFianlimabPhase 2Not yet recruitingUniversity of ChicagoJan 16, 2026
    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerFianlimabPhase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns HopkinsDec 15, 2025
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisRelatlimabPhase 1 / Phase 2RecruitingUniversity of Wisconsin, MadisonDec 15, 2025
    IL-17 Blockade to Decrease irAEs (REPLAY)RelatlimabPhase 1RecruitingDuke UniversityNov 20, 2025
    Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaFianlimabPhase 2RecruitingIntergroupe Francophone de Cancerologie ThoraciqueNov 18, 2025
    Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic MelanomaRelatlimab—RecruitingJohn KirkwoodOct 31, 2025
    Efti in Patients With Hormone Receptor Positive/HER2-neg Breast CancerEftilagimod alfaPhase 2Not yet recruitingGeorge Washington UniversityAug 5, 2025
    Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)Eftilagimod alfaPhase 3Active, not recruitingImmutep S.A.S.Dec 10, 2024
    Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialEftilagimod alfaPhase 2Active, not recruitingMaria Sklodowska-Curie National Research Institute of OncologyNov 13, 2023
    A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)FavezelimabPhase 1 / Phase 2Active, not recruitingMerck Sharp & Dohme LLCMay 6, 2023
    Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)FavezelimabPhase 1 / Phase 2Active, not recruitingMerck Sharp & Dohme LLCJun 24, 2021
    Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)FavezelimabPhase 3RecruitingMerck Sharp & Dohme LLCApr 3, 2018
    Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid TumorsEftilagimod alfaPhase 1Active, not recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAug 17, 2017

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Non-small cell lung carcinoma0.39
    • Autoimmune thyroid disease0.27
    • Head and neck squamous cell carcinoma0.23
    • Gastroesophageal junction adenocarcinoma0.22
    • Urinary bladder carcinoma0.22
    • Gastric neoplasm0.19
    • Cancer0.14

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630881, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P18627, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.